486 related articles for article (PubMed ID: 17368496)
21. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
[TBL] [Abstract][Full Text] [Related]
22. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
[TBL] [Abstract][Full Text] [Related]
23. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
Zhang Y; Ye L; Ding Q; Fang Z; Yao M; Shi D
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):545-7. PubMed ID: 11832106
[TBL] [Abstract][Full Text] [Related]
24. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Suzuki K; Takahashi K
J Urol; 2006 Oct; 176(4 Pt 1):1387-91. PubMed ID: 16952639
[TBL] [Abstract][Full Text] [Related]
25. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
26. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
Hill M; Petrik R; Hampl R; Stárka L
Horm Metab Res; 1996 Oct; 28(10):562-4. PubMed ID: 8934217
[TBL] [Abstract][Full Text] [Related]
27. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
28. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
29. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH).
Monti S; Di Silverio F; Toscano V; Martini C; Lanzara S; Varasano PA; Sciarra F
J Androl; 1998; 19(4):428-33. PubMed ID: 9733145
[TBL] [Abstract][Full Text] [Related]
30. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
Titus MA; Gregory CW; Ford OH; Schell MJ; Maygarden SJ; Mohler JL
Clin Cancer Res; 2005 Jun; 11(12):4365-71. PubMed ID: 15958619
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor isoforms in human and rat prostate.
Xia SJ; Hao GY; Tang XD
Asian J Androl; 2000 Dec; 2(4):307-10. PubMed ID: 11202423
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
[TBL] [Abstract][Full Text] [Related]
33. Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.
Pejčić T; Tosti T; Tešić Ž; Milković B; Dragičević D; Kozomara M; Čekerevac M; Džamić Z
Prostate; 2017 Jul; 77(10):1082-1092. PubMed ID: 28594074
[TBL] [Abstract][Full Text] [Related]
34. Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
Geller J; Albert J; de la Vega D; Loza D; Stoeltzing W
Cancer Res; 1978 Nov; 38(11 Pt 2):4349-52. PubMed ID: 81107
[TBL] [Abstract][Full Text] [Related]
35. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
36. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
37. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study.
Michalakis K; Williams CJ; Mitsiades N; Blakeman J; Balafouta-Tselenis S; Giannopoulos A; Mantzoros CS
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):308-13. PubMed ID: 17301264
[TBL] [Abstract][Full Text] [Related]
38. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
39. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.
Vignozzi L; Cellai I; Santi R; Lombardelli L; Morelli A; Comeglio P; Filippi S; Logiodice F; Carini M; Nesi G; Gacci M; Piccinni MP; Adorini L; Maggi M
J Endocrinol; 2012 Jul; 214(1):31-43. PubMed ID: 22562653
[TBL] [Abstract][Full Text] [Related]
40. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]